Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

G6PD as a predictive marker for glioma risk, prognosis and chemosensitivity

G6PD as a predictive marker for glioma risk, prognosis and chemosensitivity Purpose Glucose-6-phosphate dehydrogenase (G6PD) is a key enzyme preventing cells from oxidative damage and has been reported to have tumor-promoting roles. This study aims to comprehensively evaluate the predictive values of G6PD on brain tumor risk, prognosis and chemo-resistance. Methods A retrospective 13-year cohort study analyzing cancer risk using the Taiwan National Health Insurance Research Database (4066 G6PD deficiency patients and 16,264 controls) was conducted. Furthermore, RNAseq and clinical data of grade II–III glioma (LGG, n = 515) and glioblastoma (GBM, n = 155) were downloaded from The Cancer Genome Atlas (TCGA) and analyzed. Bioinformatics methods were applied to build a glioma prognostication model and to predict response to chemotherapy based on tumor G6PD-related gene expressions. The predicted results were validated in another glioma cohort GSE 16011 and in KALS1 cell line. Results G6PD-dificient patients were found to have an increased risk for cancers, especially for brain tumor (adjusted hazard ratio (HR) 10.5, 95% CI 1.03–7.60). Furthermore, higher tumor G6PD expression was associated with poor patient survival in LGG, but not in GBM. A prognostication model using expression levels of G6PD and 9 related genes (PSMA2, PSMB8, SHFM1, GSS, GSTK1, MGST2, POLD3, MSH2, MSH6) could independently predict LGG patient http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Neuro-Oncology Springer Journals

G6PD as a predictive marker for glioma risk, prognosis and chemosensitivity

Download PDF
10 pages
Read Article

Loading next page...
 
/lp/springer_journal/g6pd-as-a-predictive-marker-for-glioma-risk-prognosis-and-RrsyP05Znd
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Neurology
ISSN
0167-594X
eISSN
1573-7373
DOI
10.1007/s11060-018-2911-8
pmid
29845423
Publisher site
See Article on Publisher Site

Abstract

Purpose Glucose-6-phosphate dehydrogenase (G6PD) is a key enzyme preventing cells from oxidative damage and has been reported to have tumor-promoting roles. This study aims to comprehensively evaluate the predictive values of G6PD on brain tumor risk, prognosis and chemo-resistance. Methods A retrospective 13-year cohort study analyzing cancer risk using the Taiwan National Health Insurance Research Database (4066 G6PD deficiency patients and 16,264 controls) was conducted. Furthermore, RNAseq and clinical data of grade II–III glioma (LGG, n = 515) and glioblastoma (GBM, n = 155) were downloaded from The Cancer Genome Atlas (TCGA) and analyzed. Bioinformatics methods were applied to build a glioma prognostication model and to predict response to chemotherapy based on tumor G6PD-related gene expressions. The predicted results were validated in another glioma cohort GSE 16011 and in KALS1 cell line. Results G6PD-dificient patients were found to have an increased risk for cancers, especially for brain tumor (adjusted hazard ratio (HR) 10.5, 95% CI 1.03–7.60). Furthermore, higher tumor G6PD expression was associated with poor patient survival in LGG, but not in GBM. A prognostication model using expression levels of G6PD and 9 related genes (PSMA2, PSMB8, SHFM1, GSS, GSTK1, MGST2, POLD3, MSH2, MSH6) could independently predict LGG patient

Journal

Journal of Neuro-Oncology – Springer Journals

Published: May 29, 2018

References

  • Glucose-6-phosphate dehydrogenase, NADPH, and cell survival
    Stanton, RC
  • Brain glucose-6-phosphate dehydrogenase protects against endogenous oxidative DNA damage and neurodegeneration in aged mice
    Jeng, W; Loniewska, MM; Wells, PG
  • Neuroprotection by transgenic expression of glucose-6-phosphate dehydrogenase in dopaminergic nigrostriatal neurons of mice
    Mejias, R; Villadiego, J; Pintado, CO; Vime, PJ; Gao, L; Toledo-Aral, JJ; Echevarria, M; Lopez-Barneo, J
  • Changes in the expression of proteins associated with aerobic glycolysis and cell migration are involved in tumorigenic ability of two glioma cell lines
    Ramao, A; Gimenez, M; Laure, HJ; Izumi, C; Vida, RC; Oba-Shinjo, S; Marie, SK; Rosa, JC
  • New challenges to study heterogeneity in cancer redox metabolism
    Benfeitas, R; Uhlen, M; Nielsen, J; Mardinoglu, A
  • Glucose-6-phosphate dehydrogenase deficiency and risk of colorectal cancer in Northern Sardinia: A retrospective observational study
    Dore, MP; Davoli, A; Longo, N; Marras, G; Pes, GM
  • Changes in incidence and sex ratio of glucose-6-phosphate dehydrogenase deficiency by population drift in Taiwan
    Chien, YH; Lee, NC; Wu, ST; Liou, JJ; Chen, HC; Hwu, WL
  • Regulation of the pentose phosphate pathway in cancer
    Jiang, P; Du, W; Wu, M
  • Glucose-6-phosphate dehydrogenase: a biomarker and potential therapeutic target for cancer
    Zhang, C; Zhang, Z; Zhu, Y; Qin, S
  • Metabolic genes in cancer: their roles in tumor progression and clinical implications
    Furuta, E; Okuda, H; Kobayashi, A; Watabe, K
  • High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Stupp, R; Brada, M; Bent, MJ; Tonn, JC; Pentheroudakis, G; Group, EGW
  • IDH1 and IDH2 mutations in gliomas
    Cohen, AL; Holmen, SL; Colman, H
  • Altered metabolic landscape in IDH-mutant gliomas affects phospholipid, energy, and oxidative stress pathways
    Fack, F; Tardito, S; Hochart, G; Oudin, A; Zheng, L; Fritah, S; Golebiewska, A; Nazarov, PV; Bernard, A; Hau, AC; Keunen, O; Leenders, W; Lund-Johansen, M; Stauber, J; Gottlieb, E; Bjerkvig, R; Niclou, SP
  • Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas
    Chaichana, KL; McGirt, MJ; Laterra, J; Olivi, A; Quinones-Hinojosa, A
  • Low-grade gliomas in adults
    Grier, JT; Batchelor, T
  • Gemcitabine plus radiation therapy for high-grade glioma: long-term results of a phase 1 dose-escalation study
    Kim, MM; Camelo-Piragua, S; Schipper, M; Tao, Y; Normolle, D; Junck, L; Mammoser, A; Betz, BL; Cao, Y; Kim, CJ; Heth, J; Sagher, O; Lawrence, TS; Tsien, CI
  • Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma
    Ahmad, F; Dixit, D; Sharma, V; Kumar, A; Joshi, SD; Sarkar, C; Sen, E
  • Risk of leukaemia in children infected with enterovirus: a nationwide, retrospective, population-based, Taiwanese-registry, cohort study
    Lin, JN; Lin, CL; Lin, MC; Lai, CH; Lin, HH; Yang, CH; Sung, FC; Kao, CH
  • Risk of Nephrotic Syndrome following Enteroviral Infection in Children: A Nationwide Retrospective Cohort Study
    Lin, JN; Lin, CL; Yang, CH; Lin, MC; Lai, CH; Lin, HH; Kao, CH
  • Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization
    Budczies, J; Klauschen, F; Sinn, BV; Gyorffy, B; Schmitt, WD; Darb-Esfahani, S; Denkert, C
  • A landscape of pharmacogenomic interactions in cancer
    Iorio, F; Knijnenburg, TA; Vis, DJ; Bignell, GR; Menden, MP; Schubert, M; Aben, N; Goncalves, E; Barthorpe, S; Lightfoot, H; Cokelaer, T; Greninger, P; Dyk, E; Chang, H; Silva, H; Heyn, H; Deng, X; Egan, RK; Liu, Q; Mironenko, T; Mitropoulos, X; Richardson, L; Wang, J; Zhang, T; Moran, S; Sayols, S; Soleimani, M; Tamborero, D; Lopez-Bigas, N; Ross-Macdonald, P; Esteller, M; Gray, NS; Haber, DA; Stratton, MR; Benes, CH; Wessels, LFA; Saez-Rodriguez, J; McDermott, U; Garnett, MJ
  • Moderate G6PD deficiency increases mutation rates in the brain of mice
    Felix, K; Rockwood, LD; Pretsch, W; Nair, J; Bartsch, H; Bornkamm, GW; Janz, S
  • Glucose-6-phosphate dehydrogenase deficiency and the incidence of cancer
    Beaconsfield, P; Rainsbury, R; Kalton, G
  • Microbiome, inflammation and colorectal cancer
    Chen, J; Pitmon, E; Wang, K
  • Restoring oxidant signaling suppresses proarthritogenic T cell effector functions in rheumatoid arthritis
    Yang, Z; Shen, Y; Oishi, H; Matteson, EL; Tian, L; Goronzy, JJ; Weyand, CM
  • The cellular response to oxidatively induced DNA damage and polymorphism of some DNA repair genes associated with clinicopathological features of bladder cancer
    Savina, NV; Nikitchenko, NV; Kuzhir, TD; Rolevich, AI; Krasny, SA; Goncharova, RI
  • The ATM kinase inhibitor KU-55933 provides neuroprotection against hydrogen peroxide-induced cell damage via a gammaH2AX/p-p53/caspase-3-independent mechanism: Inhibition of calpain and cathepsin D
    Chwastek, J; Jantas, D; Lason, W
  • Cells redox environment modulates BRCA1 expression and DNA homologous recombination repair
    Wilson, A; Yakovlev, VA
  • Prognostic value and their clinical implication of 89-gene signature in glioma
    Shahid, M; Cho, KM; Nguyen, MN; Choi, TG; Jo, YH; Aryal, SN; Yoo, JY; Yun, HR; Lee, JW; Eun, YG; Lee, JS; Kang, I; Ha, J; Yoon, HJ; Kim, SY; Kim, SS
  • Integrated analysis of genome-wide DNA methylation, gene expression and protein expression profiles in molecular subtypes of WHO II–IV gliomas
    Wang, ZL; Zhang, CB; Cai, JQ; Li, QB; Wang, Z; Jiang, T
  • Disrupting G6PD-mediated Redox homeostasis enhances chemosensitivity in colorectal cancer
    Ju, HQ; Lu, YX; Wu, QN; Liu, J; Zeng, ZL; Mo, HY; Chen, Y; Tian, T; Wang, Y; Kang, TB; Xie, D; Zeng, MS; Huang, P; Xu, RH
  • Identification of proteins responsible for adriamycin resistance in breast cancer cells using proteomics analysis
    Wang, Z; Liang, S; Lian, X; Liu, L; Zhao, S; Xuan, Q; Guo, L; Liu, H; Yang, Y; Dong, T; Liu, Y; Liu, Z; Zhang, Q
  • ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway
    Yin, X; Tang, B; Li, JH; Wang, Y; Zhang, L; Xie, XY; Zhang, BH; Qiu, SJ; Wu, WZ; Ren, ZG
  • Phospho-DeltaNp63alpha/SREBF1 protein interactions: bridging cell metabolism and cisplatin chemoresistance
    Huang, Y; Bell, LN; Okamura, J; Kim, MS; Mohney, RP; Guerrero-Preston, R; Ratovitski, EA
  • Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas
    Fack, F; Espedal, H; Keunen, O; Golebiewska, A; Obad, N; Harter, PN; Mittelbronn, M; Bahr, O; Weyerbrock, A; Stuhr, L; Miletic, H; Sakariassen, PO; Stieber, D; Rygh, CB; Lund-Johansen, M; Zheng, L; Gottlieb, E; Niclou, SP; Bjerkvig, R
  • The ubiquitin-proteasome pathway and its role in cancer
    Mani, A; Gelmann, EP
  • A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas
    Odia, Y; Kreisl, TN; Aregawi, D; Innis, EK; Fine, HA
  • A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas
    Raizer, JJ; Chandler, JP; Ferrarese, R; Grimm, SA; Levy, RM; Muro, K; Rosenow, J; Helenowski, I; Rademaker, A; Paton, M; Bredel, M
  • A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma
    VeldhuijzenZanten, SEM; El-Khouly, FE; Jansen, MHA; Bakker, DP; Sanchez Aliaga, E; Haasbeek, CJA; Wolf, NI; Zwaan, CM; Vandertop, WP; Vuurden, DG; Kaspers, GJL